ArticleFrontiers in molecular biosciences2025
Peripheral myelin protein 2 is underexpressed in early-onset colorectal cancer and inhibits metastasis.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The occurrence and fatality rates of early-onset colorectal cancer (EOCRC) are increasing, with metastasis being one of the primary causes of the high mortality rate in EOCRC patients. Currently, there is a shortage of biomarkers for diagnosis and targets for treatment with optimal efficacy and reliability. This study aims to identify biomarkers associated with metastasis to provide effective diagnostic strategies for EOCRC patients. Methods: Expression datasets were retrieved from The Cancer Genome Atlas (TCGA) database and analyzed for differentially expressed genes (DEGs). Subsequently, weighted gene co-expression network analysis (WGCNA) was performed to identify gene modules associated with EOCRC metastasis. Feature genes were selected using machine learning and tdiagnostic performance of these genes was assessed with receiver operating characteristic (ROC) curves. We validated peripheral myelin protein 2 (PMP2) expression levels in EOCRC tissues at the molecular and protein levels using quantitative reverse transcription polymerase chain reaction (qRT-PCR) and immunohistochemistry (IHC). Finally, the invasive and migratory capabilities of PMP2 were assessed in this study using Transwell assays. Results: The analysis identified 1,411 DEGs in EOCRC and 3,434 DEGs in late-onset colorectal cancer (LOCRC). Subsequently, WGCNA filtered out module genes specifically associated with metastasis in EOCRC, leading to 44 genes. We identified four feature genes by analyzing these genes using machine learning algorithms and taking the intersection: LINC02268, AC092652.1, GRIK1, and PMP2. The ROC curve indicated that these four genes are vitally involved in EOCRC. Further, qRT-PCR and IHC highlighted that PMP2 was downregulated in EOCRC tumor tissues compared to normal tissues. Moreover, Transwell assays revealed that PMP2 inhibited the invasion and migration of EOCRC. Conclusion: PMP2 has low expression in EOCRC tissues and inhibits EOCRC metastasis, serving as a potential biomarker and therapeutic target for EOCRC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.